OBJECTIVE Individuals with early-onset dysexecutive Alzheimer's disease (dAD) have high rates of failed performance validity testing (PVT), which can lead to symptom misinterpretation and misdiagnosis. METHOD The aim of this retrospective study is to evaluate rates of failure on a common PVT, the test of memory malingering (TOMM), in a sample of clinical patients with biomarker-confirmed early-onset dAD who completed neuropsychological testing. RESULTS We identified seventeen patients with an average age of symptom onset at 52.25 years old. Nearly fifty percent of patients performed below recommended cut-offs on Trials 1 and 2 of the TOMM. Four of six patients who completed outside neuropsychological testing were misdiagnosed with alternative etiologies to explain their symptomatology, with two of these patients' performances deemed unreliable based on the TOMM. CONCLUSIONS Low scores on the TOMM should be interpreted in light of contextual and optimally biological information and do not necessarily rule out a neurodegenerative etiology.

中文翻译：

---

对早发性功能障碍性阿尔茨海默病患者的记忆欺骗和误诊测试表现不佳。

目标 早发性执行障碍性阿尔茨海默病 (dAD) 患者的绩效有效性测试 (PVT) 失败率很高，这可能导致症状误解和误诊。方法 本回顾性研究的目的是评估常见 PVT 的失败率，即记忆诈病测试 (TOMM)，样本为完成神经心理测试且经生物标志物证实的早发性 dAD 临床患者。结果 我们确定了 17 名患者，其症状发作的平均年龄为 52.25 岁。在 TOMM 试验 1 和试验 2 中，近 50% 的患者表现低于推荐的截止值。完成外部神经心理学测试的六名患者中有四名被误诊为其他病因以解释其症状，其中两名患者的 根据 TOMM 被认为不可靠的性能。结论 TOMM 的低分应根据上下文和最佳生物学信息进行解释，并不一定排除神经退行性病因。